Pharvaris N.V.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Pharvaris N.V. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Pharvaris N.V. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Pharvaris N.V. is PHVS:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Pharvaris N.V. has its primary listing on NASDAQ. You can trade Pharvaris N.V. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Pharvaris N.V. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Pharvaris N.V. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Pharvaris N.V..